Healthcare

Cencora, Inc. (COR)

$264.84
+0.06%
$52.4B
Market Cap
20.7
P/E Ratio
0.65
Beta
0.89%
Dividend Yield
Piotroski 5/9Altman Z 4.8 SafeBeneish M -2.54 CleanROIC−WACC +2.5%

Quantitative Summary

Deterministic

At 20.7x earnings — a 68% discount to the sector average of 65.2x — COR is in the lower valuation range. Financial health is average: Piotroski 5/9, Altman Z 4.8. DCF fair value of $333 suggests 4% upside based on model assumptions.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The capital allocation profile reveals a company generating an ROIC-WACC spread of +2.9%, indicating modest value creation relative to its cost of capital, despite a Piotroski F-Score of 5/9 suggesting moderate financial strength rather than robust improvement. The DuPont decomposition exposes a highly leveraged engine driving an 89.0% ROE; this return is not fueled by operational efficiency or pricing power but entirely by extreme leverage, evidenced by an equity multiplier of 43.84x that compresses net margins to just 0.5%. While the Altman Z-Score of 4.8 and negative Beneish M-Score of -2.54 signal low distress probability and limited earnings manipulation risk respectively, the razor-thin operating leverage leaves profitability highly sensitive to revenue fluctuations, even as top-line growth remains healthy at 9.3% year-over-year.

Valuation metrics present a divergence between intrinsic value models and current market pricing, with the stock trading at a premium P/E of 39.1x compared to its implied fair value derived from DCF analysis. The model prices in aggressive long-term free cash flow growth averaging 8.7% over the next decade, resulting in an upside potential calculated at $359 per share and a theoretical gain of 14.3%. However, this valuation premium assumes sustained execution that must justify the current multiple given the company's reliance on financial leverage rather than margin expansion or asset turnover efficiency to generate returns.

Risk-adjusted performance data indicates significant idiosyncratic alpha generation with an annual Fama-French Alpha of 22.13%, outperforming standard factor benchmarks, yet this is counterbalanced by a distinct value tilt (HML: 0.207) and neutral profitability exposure. The risk picture further deteriorates when examining insider dynamics, which show $3,637,196 in net selling over the past ninety days; such executive disposition combined with high leverage warrants close monitoring of capital structure stability against potential market downturns that could rapidly erode equity value due to limited operational buffers.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive
Market Price
$264.84
Fair Value
$332
Implied Upside
+25.3%
$332IMPLIED FAIR VALUEUNDERVALUEDOVERUNDER
Growth Rate (Y1–5)7%
-10%20%50%
Discount Rate (WACC)8.7%
5%12.5%20%

5-year two-stage DCF. Terminal growth 3%. Default sliders match the pre-computed base case. Drag to explore scenarios. Not investment advice.

Reverse DCFMarket-Implied
9.9%annual FCF growth priced in at $264.84

The growth rate the market implicitly expects over the next 10 years to justify today's price. Compare with historical growth of 9% YoY revenue.

Sensitivity Matrix

TG ↓ / WACC →6.7%8.7%10.7%
2%$425$290$217
3%$527$333$240
4%$704$395$270

Center = base case. Green = >10% upside, Red = >10% downside vs $264.84.

Pre-computed DCF: WACC=8.7%, terminal growth 3%. Fair value $333 (+4.4%). Not investment advice.

Valuation Context

20.7x
COR P/E
65.2x
Sector Avg
43.6x
5Y Avg P/E
-68%
vs Sector

Currently trading 12% below its 5-year average P/E of 43.6x.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Technical Setup

AI Generated

Cencora, Inc. is currently trading at $264.75 within the healthcare sector, presenting a specific technical configuration regarding its relative valuation against moving average envelopes. At this price point, the stock's position relative to its short-term and long-term trend lines suggests it may be testing key support or resistance zones that often define mean-reversion opportunities. When a security trades near the lower boundary of an SMA envelope, historical patterns frequently indicate a potential bounce back toward the centerline if momentum shifts, whereas proximity to the upper band might signal a cooling-off period before regression occurs. The current level implies that market participants are evaluating whether this price represents a temporary deviation from the established trend or a structural shift in valuation dynamics. The absence of additional volume data or specific moving average slopes limits the precision of predicting immediate directionality, yet the static price figure invites analysis of how far removed it is from historical averages. If $264.75 sits significantly below recent mean prices, it could theoretically offer attractive entry points for those anticipating a statistical return to equilibrium; conversely, if it hovers near historical highs within the envelope structure, caution regarding overextension might be warranted. This relative positioning does not dictate future movement but rather highlights areas where price discovery often pauses before resuming its established trajectory or reversing course based on broader market sentiment and sector-specific catalysts inherent to the healthcare industry.

RSI (14)
SMA 50
SMA 200

Quant Health Deep Dive

5/9
Piotroski F-Score
Average — mixed operational signals
4.8
Altman Z-Score
Safe Zone — above 3.0 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-2.54
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

3.6%
Gross Margin
0.5%
Net Margin
11.3%
ROIC
8.7%
WACC
ROIC − WACC Spread: +2.5%— Positive spread.
+9.3%
Revenue Growth (YoY)
+3.0%
Earnings Growth (YoY)
3.2B
Free Cash Flow
14%
FCF Payout Ratio

✅ Conservative payout — room for dividend increases.

DuPont Analysis — ROE Decomposition

Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.

0.5%
Net Profit Margin
NI ÷ Revenue
×
4.20x
Asset Turnover
Revenue ÷ Assets
×
43.84x
Equity Multiplier
Assets ÷ Equity
=
89.0%
Return on Equity
⚠️ High equity multiplier — ROE is being amplified by leverage, not operational excellence.

Balance Sheet Health

42.84x
Debt / Equity
0.90x
Current Ratio
6.4x
Interest Coverage
0.9x
Net Debt / EBITDA
4.89%
FCF Yield
3.7B
EBITDA

Insider Activity (Last 90 Days)

Net Insider Flow
-$4M
Net Selling
0
Buy Transactions
3
Sale Transactions
2026-03-11BATTAGLIA SILVANASold 4/7 qtrsOther8,415 shares
2026-03-11CAMPBELL ELIZABETH SSold 2/7 qtrsOther12,623 shares
2026-03-11CLEARY JAMES F. JR.Other12,623 shares
2026-03-05MILLER REDONDA M.D.Grant$200,119
2026-03-05RYERKERK LORI JGrant$200,119

Open-market buys vs sells by company insiders. Source: yfinance.

Earnings Surprise History

Q4
✓ Beat
Est: $4.10
Act: $4.42
+7.9%
Q3
✓ Beat
Est: $3.84
Act: $4.00
+4.2%
Q2
✓ Beat
Est: $3.79
Act: $3.84
+1.4%
Q1
✓ Beat
Est: $4.04
Act: $4.08
+1.0%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Dividend History

$0.6000
Latest Dividend
$2.25
2025 Total
+8.2%
YoY Growth
3 yrs
Consecutive Increases
Annual Dividends per Share
$4.86
2019
$6.59
2020
$6.82
2021
$1.87
2022
$1.97
2023
$2.08
2024
$2.25
2025
$1.20
2026
DateAmountChange
2026-05-15$0.60000.0%
2026-02-13$0.60000.0%
2025-11-14$0.6000+9.1%
2025-08-15$0.55000.0%
2025-05-16$0.55000.0%
2025-02-14$0.55000.0%
2024-11-15$0.5500+7.8%
2024-08-09$0.51000.0%
2024-05-09$0.51000.0%
2024-02-08$0.51000.0%
2023-11-10$0.5100+5.2%
2023-08-10$0.48500.0%
Stock Splits
2009-06-16: 2:12005-12-29: 2:11999-03-25: 2:1

Dividend and split data from SEC filings and market data. Amounts are per share, not adjusted for splits. Source: yfinance.

Risk Profile

20.9%
Annual Volatility
0.57
Sharpe (1Y)
0.97
Sharpe (3Y)
-16.5%
Max Drawdown (3Y)
-17.8%
Max Drawdown (5Y)

Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fama-French 5-Factor Exposure

Academic factor model decomposition — what's really driving this stock's returns.

0.13
Market β
Mkt-RF
-0.272
Size (SMB)
Large-cap tilt
+0.207
Value (HML)
Value tilt
+0.036
Profit (RMW)
Neutral
+0.021
Invest (CMA)
Neutral
Alpha (annual): +22.13%
R²: 2.5%of variance explained by 5 factors

Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.

Fundamentals

13.6
Forward P/E
0.64
PEG Ratio
15.42
Price/Book
2M
Avg Volume
$377.54
52W High
$244.82
52W Low
15%
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$8.9B
Tracked Passive Exposure
8
ETFs Holding COR
0.14%
Avg Weight in ETFs
$6.4T
Total ETF AUM

When investors buy or sell ETFs like IWP or XHS, the fund manager is mechanically forced to buy or sell COR shares regardless of Cencora, Inc.'s individual fundamentals. We estimate $8.9B of passive capital is structurally linked to COR through 8 tracked ETFs. This substantial passive exposure means that ETF inflows and outflows — not company fundamentals — can dominate daily volume on this stock.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in Cencora, Inc. to visualize passive redemption contagion across ETFs and collateral stocks.

COR Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
COREpicenterVTIETFVOOETFIVVETFLLYLow RiskLLYLow RiskJNJLow RiskUNHMed RiskJNJLow Risk
COR Price Drop (%)0

If Cencora, Inc. (COR) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies ELI LILLY + CO (LLY) as the most exposed collateral stock, sharing 1 ETFs with COR. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 33 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

COR Ownership Dynamics

Passive funds hold 1 in every 7 COR shares, reducing daily market volatility.

Ticker
COR
Total Shares
195M
ETF Lock-Up
14.9%
Display Mode
Total Float Impact
14.9%Locked Float

Cencora, Inc. (COR) exerts measurable gravity on the passive index market, currently representing 1.9% of the IWP (IWP) and 1.4% of the XHS (XHS). Across 32 tracked ETFs, approximately 29M shares (14.9% of float) are held by passive funds and rarely trade on the open market. This level of passive ownership means index rebalances can create outsized volume events.

Float lock-up computed from 32 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

COR Institutional Volume Profile

252-day volume distribution by price level. The Point of Control (POC) marks the price where the most institutional volume transacted — an implicit support/resistance floor.

TICKER
COR
PRICE
$264.84
FLOOR (POC)
$294.36
STRENGTH
High
$248$255$261$268$264.84$275$281$28811%$294POC 13%$301$308$314$321$327$334$3418%$347$3546%$3608%$367$374
Focus Zone
Point of Control (POC) Support (below price) Resistance (above price) Current Price

The highest-volume price zone for Cencora, Inc. over the past year sits near $294.36 (13% of 252-day volume). The current price of $264.84 sits 10.0% below the POC — suggesting potential mean-reversion upside if institutional demand reasserts at this level. The highly concentrated volume profile (13% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.

Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.

COR Capital Efficiency

How efficiently does Cencora, Inc. convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$3.2B
EBITDA
$3.7B
FCF Conversion
86%
Reinvestment Rate
14%
86% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
11.3%
ROIC − WACC Spread
2.5%

Cencora, Inc. converts 86% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. The positive ROIC-WACC spread of 2.5% confirms that reinvested capital creates shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-086,460$255.66$1.7M
2026-04-273,108$308.19$957,854.52
2026-04-24202$311.39$62,900.78
2026-04-234,770$308.30$1.5M
2026-04-227,110$312.39$2.2M
2026-04-068$324.80$2,598.4
2026-03-311,278$309.93$396,090.54
2026-03-264,364$325.08$1.4M
2026-03-2519$327.27$6,218.13
2026-03-239,623$326.91$3.1M
2026-03-116$352.19$2,113.14
2026-03-05339$368.19$124,816.41
2026-03-0236$372.14$13,397.04
2026-02-24727$366.03$266,103.81
2026-02-12788$365.70$288,171.6
2026-02-0359$363.56$21,450.04
2026-01-15116$349.93$40,591.88
2025-12-29682$341.05$232,596.1
2025-12-222,089$340.93$712,202.77
2025-12-17900$341.72$307,548
2025-11-172$361.94$723.88
2025-11-1443,587$365.45$15.9M
2025-11-0413,151$340.93$4.5M
2025-10-3115$341.21$5,118.15
2025-10-3057$333.17$18,990.69
2025-10-246$328.56$1,971.36
2025-10-229$328.82$2,959.38
2025-10-21221$327.39$72,353.19
2025-10-1710,609$319.40$3.4M
2025-10-1416,041$317.00$5.1M

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Price Correlations

Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.

Peer252-Day (1Y)126-Day (6M)Direction
WTGXXNaNNaN
MCK0.7600.712High co-movement
CAH0.6710.659Moderate
WELL0.4240.369Moderate
EVRG0.3600.299Moderate
FE0.3530.319Moderate
PPL0.3440.293Moderate
BSX0.3390.366Moderate
NI0.3350.249Moderate
CMS0.3290.335Moderate

Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.

Compare COR to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.